SLOW ACHIEVEMENT OF HCV-RNA UNDETECTABILITY IN CIRRHOTIC PATIENTS TREATED WITH SOFOSBUVIR plus RIBAVIRIN: POSSIBLE CLINICAL IMPLICATIONS IN THE LIVER TRANSPLANT LIST MANAGEMENT

Autor: Sforza, Daniele, Lenci, Ilaria, Manuelli, Matteo, Cento, Valeria, Rendina, Maria, Maria, Francesca Donato, Martina, Milana, Marianna, Aragri, Velia, Chiara Di Maio, Amal, Abedrabbo, Federico, Malinverno, Sara, Monico, Maria, Laura Ponti, Roberta, Canu, Roberto, Ganga, Milanesi, Luciano, Di Leo, Alfredo, Perno, Carlo Federico, Ceccherini-Silberstein, Francesca, Colombo, Massimo, Angelico, Mario, Tisone, Giuseppe

Publikováno v: Transplant international 28 (2015): 22–23.
info:cnr-pdr/source/autori:Sforza, Daniele; Lenci, Ilaria; Manuelli, Matteo; Cento, Valeria; Rendina, Maria; Maria, Francesca Donato; Martina, Milana; Marianna, Aragri; Velia, Chiara Di Maio; Amal, Abedrabbo; Federico, Malinverno; Sara, Monico; Maria, Laura Ponti; Roberta, Canu; Roberto, Ganga; Milanesi, Luciano; Di Leo, Alfredo; Perno, Carlo Federico; Ceccherini-Silberstein, Francesca; Colombo, Massimo; Angelico, Mario; Tisone, Giuseppe/titolo:SLOW ACHIEVEMENT OF HCV-RNA UNDETECTABILITY IN CIRRHOTIC PATIENTS TREATED WITH SOFOSBUVIR plus RIBAVIRIN: POSSIBLE CLINICAL IMPLICATIONS IN THE LIVER TRANSPLANT LIST MANAGEMENT/doi:/rivista:Transplant international/anno:2015/pagina_da:22/pagina_a:23/intervallo_pagine:22–23/volume:28

Sofosbuvir (SOF) treatment ± ribavirin (RBV) prior to LT has the potential to change the HCV recurrence after Liver Transplantation (LT). This approach has been reported to avoid graft reinfection in compensated patients with hepatocellular carcinom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::5f58904404566901e838ed0a7393e0ac
http://www.cnr.it/prodotto/i/361408